GenSpera, Inc. Information

GenSpera unlocks conventional thinking to conceive, design, and develop curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity and minimize side effects. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types. The US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in patients with hepatocellular carcinoma (liver cancer). Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients (brain cancer).